FDA Warns altRx Over Compounded GLP-1 Labels and "Clinically Proven" Weight Loss Claims
On June 8, 2026, FDA issued a warning letter to Trinity HealthCare Supply, LLC dba altRx after a May 2026 review of altrx.com, which offers compounded semaglutide and tirzepatide products. FDA says pictured labels identify "altRx" as if it were the compounder "when in fact it is not," and cites claims that "GLP-1s are clinically proven medications" offering "clinically proven weight loss," which FDA says represent unapproved compounded products as evaluated for safety and effectiveness when they have not been. FDA requested a written response within 15 business days.
What this means"Same active ingredient" marketing can blur the line between an FDA-approved drug and a compounded copy that has never been through FDA review — a distinction worth understanding before ordering through any telehealth platform.
Source: FDA original ↗